21120-75-2Relevant academic research and scientific papers
COMPOUNDS AND METHODS FOR TREATING, DETECTING, AND IDENTIFYING COMPOUNDS TO TREAT APICOMPLEXAN PARASITIC DISEASES
-
Page/Page column 107-108, (2017/07/14)
Disclosed herein; are novel compounds for treating apicomplexan parasite related disorders, methods for their use; cell line and non-human animal models of the dormant parasite phenotype and methods for their use in identifying new drugs to teat apicomplexan parasite related disorders, and biomarkers to identify disease due to the parasite and its response to treatment.
Lead optimisation of selective non-zinc binding inhibitors of MMP13. Part 2
De Savi, Chris,Morley, Andrew D.,Nash, Ian,Karoutchi, Galith,Page, Ken,Ting, Attilla,Gerhardt, Stefan
supporting information; experimental part, p. 271 - 277 (2012/02/16)
Directed screening has identified a novel series of non-zinc binding MMP13 inhibitors that possess good levels of activity whilst demonstrating excellent selectivity over related MMPs. A lead optimisation campaign has delivered compounds with enhanced MMP
Selective non zinc binding inhibitors of MMP13
Savi, Chris De,Morley, Andrew D.,Ting, Attilla,Nash, Ian,Karabelas, Kostas,Wood, Christine M.,James, Michael,Norris, Stephen J.,Karoutchi, Galith,Rankine, Neil,Hamlin, Gordon,MacFaul, Philip A.,Ryan, David,Baker, Sarah V.,Hargreaves, David,Gerhardt, Stefan
scheme or table, p. 4215 - 4219 (2011/08/06)
Directed screening has identified a novel series of MMP13 inhibitors that possess good levels of activity whilst possessing excellent selectivity over related MMPs. The binding mode of the series has been solved by co-crystallisation and demonstrates an interesting mode of inhibition without interaction with the catalytic zinc atom.
